To summarize, caution should be used in the administration of TNFα inhibitors in compensated patients, who need to be monitored by ultrasound imaging; but they are not suitable for patients with decompensated liver disease because of their increased risk of potentially serious infections [97]. This evidence concerns the gene TNF and infection.